IRCT2013031212419N2
Recruiting
Phase 3
Clinical trial of recovery rate comparison in patients with unexplained chronic cough in the two groups receiving oral cetirizine with and without inhaled budesonide.
The budget will be funded by researchers.0 sites68 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The budget will be funded by researchers.
- Enrollment
- 68
- Status
- Recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age over 18 years; unexplained chronic cough for more than 8 weeks; absence of underling cardiac diseases; do not using smoking and drugs; absence of clinical and para\-clinical asthma evidence; normal chest x\-ray; normal spirometry; absence of eosinophilic bronchitis (sputum eosinophil percentage less than 3%); negative (normal) inhaled methacholine provocation test; signed written consent; absence of pregnancy and breast feeding; did not taking steroids during the last 3 months; do not receive any treatment for chronic cough before and during study; do not taking Angiotensin converting enzyme inhibitors (ACEI).
- •Exclusion criteria: dissatisfaction to continuing cooperation in each stage of the study; exacerbation or other accidents which requiring treatment; lack of returning within 48 hours of the deadline for second visit.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
A study comparing recovery features of patients undergoing general anaesthesia with rocuronium as muscle relaxant and recieving sugammadex or neostigmine and glycopyrollate for reversal.Health Condition 1: K402- Bilateral inguinal hernia, withoutobstruction or gangreneHealth Condition 2: K800- Calculus of gallbladder with acutecholecystitisHealth Condition 3: N920- Excessive and frequent menstruation with regular cycleCTRI/2024/04/065600Manipal Hospital
Active, not recruiting
Phase 1
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissionGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-HUALTANA Pharma AG
Active, not recruiting
Not Applicable
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissioGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-DEALTANA Pharma AG1,200
Active, not recruiting
Not Applicable
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissioGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-ATALTANA Pharma AG1,200
Recruiting
Phase 2
The effect of mucopexy surgical method on the incidence of postoperative complications.Condition 1: Grade 3 and 4 Hemorrhoids, Doppler Guided Hemorrhoidal Artery Ligation, Mucopexy with DG-HAL, Mucopexy without DG-HAL, General Surgery, Colorectal Surgery, Anorectal Diseases. Condition 2: Grade 3 and 4 Hemorrhoids, Mucopexy with DG-HAL, Mucopexy without DG-HAL, General Surgery, Colorectal Surgery, Anorectal Diseases.Hemorrhoids and perianal venous thrombosisFourth degree hemorrhoidsK64.3IRCT20190927044897N1Iran University of Medical Sciences36